

Ludwig Fischer von Weikersthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6763466/publications.pdf>

Version: 2024-02-01

6
papers

1,921
citations

1683934

5
h-index

1872570

6
g-index

6
all docs

6
docs citations

6
times ranked

2981
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1065-1075.	5.1	1,479
2	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1426-1434.	5.1	336
3	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. <i>British Journal of Cancer</i> , 2021, 124, 587-594.	2.9	79
4	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2020, 137, 250-259.	1.3	15
5	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). <i>European Journal of Cancer</i> , 2021, 147, 128-139.	1.3	9
6	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE 3). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	2.3	3